Homology models of the mutated EGFR and their response towards quinazolin analogues

Journal of Molecular Graphics and Modelling

Volumn 27, Issue 3, 2008, Pages 244-254

  Kotra, Sabitha ^a   Kumar Madala, Kishore ^b   Jamil, Kaiser ^c  

^a Mahavir Medical Research Center Hyderabad   (India)

^b GVK Bio Science Pvt Ltd   (India)

^c Indo American Cancer Institute and Research Centre   (India)

Author keywords

Affinity; CI 1033; Docking; EGFR; EKB 569; Erlotinib; Gefitinib; Homology modeling; In silico; Mutation; Quinazolin

Indexed keywords

AMINATION; AMINES; AMINO ACIDS; BINDING SITES; BIOCHEMISTRY; DOCKING; FLOW INTERACTIONS; ORGANIC ACIDS; QUALITY CONTROL; VAN DER WAALS FORCES;

AFFINITY; CI-1033; EGFR; EKB-569; ERLOTINIB; GEFITINIB; HOMOLOGY MODELING; IN SILICO; MUTATION; QUINAZOLIN;

BINDING ENERGY;

ADENOSINE TRIPHOSPHATE; AMINO ACID; AMINO ACID DERIVATIVE; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PELITINIB; PROTEIN KINASE SYK; QUINAZOLINE DERIVATIVE;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCULATION; CRYSTAL STRUCTURE; DATA BASE; DRUG RECEPTOR BINDING; ELECTRICITY; ENERGY; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; AMINO ACIDS; BINDING SITES; CATALYTIC DOMAIN; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION, MISSENSE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY, PROTEIN; THERMODYNAMICS;

EID: 53749091386     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2008.04.010     Document Type: Article

References (38)

1. Alroy I., and Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410 (1997) 83-86
2. Yaish P., Gazit A., Gilon C., and Levitzki A. Blocking of EGF dependent cell proliferation by EGF receptor kinase inhibitors. Science 242 (1988) 933-935
3. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82 (1999) 231-239
4. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 (2001) S3-8S
5. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 (2002) 2-8
6. Khazaie K., Schirrmacher V., and Lichtner R.B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. 12 (1993) 255-274
7. Pedersen M.W., and Poulsen H.S. Epidermal growth factor receptor in cancer therapy. Sci. Med. 8 (2002) 206-217
8. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
9. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., Fujii T., and Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 3 (2004) 465-472
10. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., Bulmer S.E., Frank D.A., Hahn W.C., Sellers W.R., and Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2 (2005) e313
11. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
12. Assefa H., Kamath S., and Buolamwini J.K. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J. Comput. Aid. Mol. Des. 17 (2003) 475-493
13. Traxler P., and Lydon N. Recent advances in protein tyrosine kinase inhibitors. Drugs Fut. 20 (1995) 1261-1274
14. Traxler P., and Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 82 (1999) 195-206
15. Morin M.J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19 (2000) 6574-6583
16. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
17. Hubbard S.R. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. 12 (2002) 735-741
18. Dancey J., and Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2 (2003) 296-313
19. International conference on bioinformatics of genome regulation and structure. Novosibirsk, Russia, 2006.
20. INSIGHT II Molecular Modelling Package, Accelrys, San Diego, MSI, USA, 1997.
21. Bairoch A., and Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res. 28 (2000) 45-48
22. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., and Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
23. Atwell S., Adams J.M., Badger J., Buchanan M.D., Feil I.K., Froning K.J., Gao X., Hendle J., Keegan K., Leon B.C., Muller-Dieckmann H.J., Nienaber V.L., Noland B.W., Post K., Rajashankar K.R., Ramos A., Russell M., Burley S.K., and Buchanan S.G. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279 (2004) 55827-55832
24. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
25. Yamaguchi H., and Hendrickson W.A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384 (1996) 484-489
26. Hubbard S.R., Wei L., Ellis L., and Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372 (1994) 746-754
27. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
28. Sali A., and Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993) 779-815
29. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., and Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29 (2000) 291-325
30. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26 (1993) 283-291
31. Binding-Site User Guide, Accelrys, San Diego, MSI, USA, 1999.
32. Gasteiger J., and Marsili M. Iterative partial equalization of orbital electronegativity. A rapid access to atomic charges. Tetrahedron 36 (1980) 3219-3228
33. Dewar M.J.S., Zoebisch E.G., Healy E.F., and Stewart J.J.P. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107 (1985) 3902-3909
34. Stamos J., Sliwkowski M.X., and Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277 (2002) 46265-46272
35. Wissner A., Brawner Floyd M.B., Rabindram S.K., Nilakantan R., Greenberger L.M., Shen R., Wang Y.F., and Tsou H.R. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg. Med. Chem. Lett. 12 (2002) 2893-2897
36. Atkins J.H., and Gershell L.J. Selective anticancer drugs. Nat. Rev. Drug Discov. 1 (2002) 491-492
37. Shewchuk L., Hassell A., Wisely B., Rocque W., Holmes W., Veal J., and Kuyper L.F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 43 (2000) 133-138
38. Rewcastle G.W., Denny W.A., Bridges A.J., Zhou H., Cody D.R., McMichael A., and Fry D.W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl) amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 38 (1995) 3482-3487